Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc., trading under the ticker symbol VOR, is at the forefront of cell and genome engineering, specifically focusing on hematopoietic stem cells (HSCs). Headquartered in Cambridge, Massachusetts, Vor Bio aims to revolutionize the treatment of hematological cancers, particularly acute myeloid leukemia (AML). The company’s pioneering platform involves engineering hematopoietic stem cells (eHSCs) to generate healthy and functional cells with beneficial modifications. These modifications protect the blood and bone marrow from the adverse effects of antigen-targeted therapies while leaving cancer cells vulnerable.
Key Products and Innovations:
- VOR33 (Trem-cel) - Vor Bio’s lead program, a CRISPR/Cas9 genome-edited allogeneic HSC transplant that lacks the CD33 protein. This product is designed to replace standard transplants for AML patients and potentially other blood cancers.
- VCAR33ALLO - A CD33-directed CAR-T cell therapy derived from healthy transplant donor cells. This approach aims to provide more potent and durable responses in the post-transplant setting without on-target toxicity.
Recent Achievements and Collaborations:
- Secured a non-exclusive worldwide license from Editas Medicine for ex-vivo Cas9 gene-edited HSC therapies.
- Partnership with Janssen for the preclinical development of CD33-deleted allografts and their synergistic effects with Janssen's CD33-targeted immunotherapy candidate.
Clinical Trials and Research:
- VBP101 Clinical Trial - Ongoing Phase 1/2a study of trem-cel in AML patients, showing promising engraftment results and hematologic protection.
- VCAR33ALLO Clinical Trial (VBP301) - A Phase 1/2 study involving CAR-T cell therapy derived from healthy transplant donors, showing initial successful dosing and manufacturing capabilities.
Financial Updates: In its latest quarterly report, Vor Bio announced positive financial outcomes, including an extended cash runway into the second half of 2025. The company is focused on executing its clinical trials and expanding its platform to include additional innovative therapies.
Future Outlook: Vor Bio is set to present at major scientific conferences, including the American Society of Hematology (ASH) Annual Meeting, where it will share significant preclinical and clinical data. The company is also looking forward to additional data releases from its clinical trials by year-end, which could further validate their treatment system for AML.
For more updates, visit www.vorbio.com.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announces dosing of first patient in VBP301 clinical trial for VCAR33ALLO, extending cash runway into second half of 2025. Initial data expected in second half of 2024. The company aims to provide a healthy transplant donor-derived CAR-T developmental therapy for AML patients, with potential to reduce relapse risk or treat evidence of relapse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) granted stock options and restricted stock units to a newly hired employee as material inducements to employment with a ten-year term and an exercise price of $2.29 per share. The options and RSUs will vest over a four-year period, subject to the employee’s continued employment with Vor Bio on such vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.37%
Tags
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) Grants Stock Options and RSUs to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.98%
Tags
Rhea-AI Summary
Vor Bio (VOR) to Participate in Fireside Chat at JMP Securities Hematology and Oncology Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Vor Bio (VOR) presents updated clinical data from Phase 1/2a study of trem-cel in AML patients, demonstrating successful engraftment in all seven patients with primary neutrophil engraftment and hematologic protection. Mylotarg dose escalation warranted based on hematologic protection and CD33-negative donor cell enrichment. VCAR33AUTO study shows 40% of patients achieving complete remission with manageable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
-
Rhea-AI Summary
Vor Bio (VOR) Reports Positive Clinical Data and Financial Results, Anticipates Upcoming Milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
Rhea-AI Summary
Vor Bio, a clinical-stage cell and genome engineering company, has granted stock options and restricted stock units (RSUs) to four newly hired employees. The stock options allow the purchase of 50,000 shares of Vor Bio's common stock at an exercise price of $2.08 per share. The RSUs represent the right to receive 75,000 shares of Vor Bio's common stock. Both the stock options and RSUs will vest over a four-year period, subject to continued employment with Vor Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will participate in upcoming investor conferences, including the Stifel 2023 Healthcare Conference, the 6th Annual Evercore ISI HealthCONx Conference, and the Piper Sandler 35th Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.43%
Tags
-
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announced that preclinical and clinical data supporting their novel platform for treating acute myeloid leukemia (AML) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting. The data includes updates from the VBP101 clinical trial and the CD33CART study, as well as other studies on AML profiling and the collaboration with Janssen. Vor Bio's CEO expressed confidence in the progress made and the potential of their next-generation transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
Rhea-AI Summary
Vor Bio grants stock options and RSUs to new employees as inducements to employment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
FAQ
What is the current stock price of Vor Biopharma (VOR)?
The current stock price of Vor Biopharma (VOR) is $0.7948 as of November 20, 2024.
What is the market cap of Vor Biopharma (VOR)?
The market cap of Vor Biopharma (VOR) is approximately 55.6M.
What is Vor Biopharma Inc. known for?
Vor Biopharma Inc. is known for its pioneering work in engineering hematopoietic stem cells (eHSCs) to treat hematological cancers, notably acute myeloid leukemia (AML).
What are the main products of Vor Biopharma Inc.?
The main products include VOR33 (Trem-cel), a genome-edited HSC transplant for AML, and VCAR33ALLO, a CD33-directed CAR-T cell therapy derived from healthy donor cells.
Where is Vor Biopharma Inc. located?
Vor Biopharma Inc. is headquartered in Cambridge, Massachusetts.
What recent achievements has Vor Biopharma Inc. made?
Recent achievements include the clearance of an IND for VCAR33ALLO by the FDA, successful in-house manufacturing runs, and securing a worldwide license from Editas Medicine.
What clinical trials are currently being conducted by Vor Biopharma Inc.?
Ongoing trials include the VBP101 study for Trem-cel in AML patients and the VBP301 study for VCAR33ALLO, a CAR-T cell therapy.
What is the potential impact of Vor Biopharma Inc.'s platform?
The platform has the potential to change the standard of care for blood cancer patients by enabling targeted therapies post-transplant, offering more effective and less toxic treatment options.
How can I stay updated on Vor Biopharma Inc.'s progress?
You can stay updated by visiting their website at www.vorbio.com and following their latest news and press releases.
What financial updates were provided by Vor Biopharma Inc. recently?
Vor Bio recently reported strong financial outcomes with an extended cash runway into the second half of 2025, highlighting robust execution of their clinical trials.
What upcoming milestones is Vor Biopharma Inc. expecting?
Upcoming milestones include data releases from their clinical trials, presentations at scientific conferences, and further advancements in their cell and genome engineering platform.
What collaborations has Vor Biopharma Inc. entered into?
Vor Bio has entered into collaborations with Editas Medicine and Janssen for the development and potential commercialization of gene-edited HSC therapies and CD33-targeted immunotherapies.
Vor Biopharma Inc.
Nasdaq:VOR
VOR Rankings
VOR Stock Data
55.63M
67.89M
1.17%
81.25%
2.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
CAMBRIDGE